# Ranolazine Implantable Cardioverter-Defibrillator Trial

Study · id `cardio:ct-nct01215253` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01215253](<https://clinicaltrials.gov/study/NCT01215253>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01215253

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems; Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1012 participants.

## Technical summary

Registry record NCT01215253. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2017-02-28 (actual). Results posted on 2018-06-15.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1012 participants (enrolled count; ClinicalTrials.gov record NCT01215253, source copy `cardio:ctgov-nct01215253-2018-08-27`, retrieved 2026-10-26)
- Start date: 2011-09 (registry gives no type) (ClinicalTrials.gov record NCT01215253, source copy `cardio:ctgov-nct01215253-2018-08-27`, retrieved 2026-10-26)
- Primary completion: 2017-02-28 (actual) (ClinicalTrials.gov record NCT01215253, source copy `cardio:ctgov-nct01215253-2018-08-27`, retrieved 2026-10-26)
- Completion: 2017-02-28 (actual) (ClinicalTrials.gov record NCT01215253, source copy `cardio:ctgov-nct01215253-2018-08-27`, retrieved 2026-10-26)
- Results first posted: 2018-06-15 (ClinicalTrials.gov record NCT01215253, source copy `cardio:ctgov-nct01215253-2018-08-27`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT01215253, source copy `cardio:ctgov-nct01215253-2018-08-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01215253-2018-08-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ranolazine Implantable Cardioverter-Defibrillator Trial
- Acronym: RAID
- Condition: Ischemic Cardiomyopathy
- Condition: Nonischemic Cardiomyopathy
- Condition: Heart Failure
- Intervention (Drug): Ranolazine
- Lead sponsor: University of Rochester
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Ventricular tachycardia (`cardio:ventricular-tachycardia`)
- Registry lists this organization as the lead sponsor: University of Rochester (`cardio:org-university-of-rochester`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial (`cardio:pubmed-30071993`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAID Trial (`cardio:pubmed-35738852`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f1c5f24d8da53fa097387afedbb13364be7015adbc244e2cf783e5835b9d8a03
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
